Search

Displaying results 5161 - 5170 of 6949 in total
  1. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.

  2. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.

  3. Drug

    Carumonam

    go.drugbank.com/drugs/DB13553
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Brodimoprim

    go.drugbank.com/drugs/DB13795
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. … Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide.

  6. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: Fizz Multivitamins for Kids W C Loz
  7. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    Bisegliptin is a compound for the treatment of type 2 diabetes.

  8. Drug

    Actoxumab

    go.drugbank.com/drugs/DB16376
    Investigational

    Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

  9. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]

  10. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.